计未超过本激励计划提交股东大会审议时公司股本总额的 20%，预留权益比例未超过本激励计划拟授 予权 益数量的 20%。 开普云信息科技股份有限公司董事会 开普云信息科技股份有限公司 一、股票期权计划预留授予部分的分配情况 占本次授 占本激励计划 获授的股票期 姓名 国籍 职务 予权益总 公告时公司股 权数量（万股） 数的比例 本总额的比例 董事会认为需要激励的其他人员（5 人） 30.00 100.00% 0.44% 合计 30.00 100.00% 0.44% 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票，累计不超过 本 计划提交股东大会审议时公司股本总额的 1%，公司全部有效期内的股权激励计划所涉及的标的股票总 数累 ...

公司简称：开普云 证券代码：688228 关于 开普云信息科技股份有限公司 上海荣正企业咨询服务（集团）股份有限公司 预留授予事项 之 独立财务顾问报告 二〇二五年八月 （二）本次实施的股票期权激励计划与股东大会审议通过的股票期权激励计 一、释义 有限公司 2025 年股票期权激励计划（草案）》。 条件购买公司一定数量股票的权利。 毕之日止。 励计划中行权即为激励对象按照激励计划设定的价格和条件购买标的股票的 行为。 易日。 励信息披露》 二、声明 （一）本独立财务顾问报告所依据的文件、材料由开普云提供，本计划所 涉及的各方已向独立财务顾问保证：所提供的出具本独立财务顾问报告所依据 的所有文件和材料合法、真实、准确、完整、及时，不存在任何遗漏、虚假或 误导性陈述，并对其合法性、真实性、准确性、完整性、及时性负责。本独立 财务顾问不承担由此引起的任何风险责任。 （二）本独立财务顾问仅就本次授予事项对开普云股东是否公平、合理， 对股东的权益和上市公司持续经营的影响发表意见，不构成对开普云的任何投 资建议，对投资者依据本报告所做出的任何投资决策而可能产生的风险，本独 立财务顾问均不承担责任。 （三）本独立财务顾问未 ...

Core Points - WanDong Medical's stock price increased by 2.67% to 18.05 yuan as of August 22, 2025, with a market capitalization of 12.69 billion yuan [1] - The company reported a decrease in the number of shareholders by 11.69% to 26,800 as of June 30, 2025, with an increase in average shareholding [2][5] - The company's mid-year report for 2025 showed a 20.46% increase in revenue to 843.33 million yuan, but a significant decline in net profit by 39.46% to 51.30 million yuan [3][5] Shareholder Changes - As of June 30, 2025, the number of shareholders decreased by 3,552, representing an 11.69% reduction [2][5] - The average number of shares held per shareholder increased from 23,100 to 26,200, with an average holding value of 452,800 yuan [2] Performance Highlights - For the first half of 2025, the company reported a total revenue of 843.33 million yuan, a year-on-year increase of 20.46% [3] - The net profit attributable to shareholders decreased by 39.46% to 51.30 million yuan, while the net profit excluding non-recurring items fell by 56.07% to 35.63 million yuan [3] - The second quarter of 2025 saw a revenue of 470 million yuan, up 20.04% year-on-year, but net profit dropped by 68.44% to 16.25 million yuan [3] Corporate Announcements - The board approved the 2025 semi-annual report and a stock option incentive plan, granting 1.2 million stock options to 14 individuals at an exercise price of 15.05 yuan per share [4][6] - The company plans to repurchase shares worth between 30 million and 60 million yuan, with a maximum repurchase price of 25 yuan per share [6]

Core Viewpoint - The company has successfully met the conditions for the first unlock period of its 2024 stock option and restricted stock incentive plan, allowing for the release of certain restricted shares [3][7][8]. Group 1: Incentive Plan Details - The first unlock period for the restricted stock will end on August 27, 2025, allowing for the release of 50% of the total granted restricted stock [7]. - A total of 119 individuals are eligible for the unlock, with 627,850 shares (0.2614% of the total share capital) set to be released [2][11]. - The company has completed all necessary approval procedures for the incentive plan, including board meetings and legal opinions [3][4][5]. Group 2: Unlock Schedule and Conditions - The shares will be available for trading starting from August 29, 2025 [9]. - The company has confirmed that the conditions for the first unlock period have been satisfied, as per the regulations outlined in the incentive plan [8]. - The plan includes a provision for a second unlock period, which will occur 12 months after the first unlock [7]. Group 3: Changes and Compliance - One individual was disqualified from the incentive plan due to leaving the company, resulting in the cancellation of 7,000 shares [14]. - The company has ensured compliance with relevant laws and regulations regarding the management of shares post-unlock [12].

Core Viewpoint - The company, Nanning Baling Technology Co., Ltd., has approved the grant of reserved stock options to the incentive objects under the first stock option incentive plan during its board meetings held on August 11, 2025 [1][6]. Group 1: Announcement Details - The company held the eighth meeting of the seventh board's remuneration and assessment committee and the twenty-first meeting of the seventh board to review the proposal for granting reserved stock options [1]. - The details of the stock option incentive plan were disclosed on August 12, 2025, through various financial news outlets and the company's official website [2]. Group 2: Public Disclosure and Review - The company publicly disclosed the list of reserved stock option incentive objects from August 12 to August 21, 2025, for a period of 10 days [2]. - No objections were raised by employees regarding the list of reserved stock option incentive objects during the public disclosure period [3]. Group 3: Verification Opinions - The remuneration and assessment committee verified that all individuals listed as incentive objects are company directors, middle management, and core technical (business) personnel, excluding independent directors and major shareholders [4]. - The committee confirmed that the listed incentive objects do not fall under any disqualifying conditions as per the relevant regulations [4][5]. - The basic information regarding the incentive objects is accurate, with no falsehoods or significant omissions [5].

北京市中伦（深圳）律师事务所 关于兆易创新科技集团股份有限公司 第二个行权期行权条件成就相关事项的 法律意见书 二〇二五年八月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦（深圳）律师事务所 关于兆易创新科技集团股份有限公司 第二个行权期行权条件成就相关事项的 法律意见书 致：兆易创新科技集团股份有限公司 北京市中伦（深圳）律师事务所（以下简称"本所"或"中伦"）接受兆易 创新科技集团股份有限公司（以下简称"兆易创新"或"公司"）的委托，担任 兆易创新实施 2023 年股票期权激励计划（ ...

Group 1 - The company held the 13th meeting of the 6th Board of Directors and the 12th meeting of the 6th Supervisory Board on August 14, 2025, where it approved the proposal to cancel part of the stock options from the 2024 stock option incentive plan [1][2] - A total of 418,000 stock options will be canceled, which includes options from 5 individuals who left the company for personal reasons and 3 individuals whose performance indicators were either qualified or unqualified [1][2] - The company has submitted the cancellation application to the Shenzhen branch of China Securities Depository and Clearing Co., Ltd., and the cancellation has been confirmed and completed as of the announcement date [1] Group 2 - The cancellation of stock options complies with the relevant laws and regulations, including the "Management Measures for Equity Incentives of Listed Companies" and the company's "2024 Stock Option Incentive Plan (Draft)" [2] - The cancellation will not affect the company's share capital structure and does not harm the interests of the company or other shareholders, particularly minority shareholders [2]

| 股票简称：万东医疗 | | 证券代码：600055 | | --- | --- | --- | | 华泰联合证券有限责任公司 | | | | 关于 | | | | 北京万东医疗科技股份有限公司 | | | | 向2025年股票期权激励计划 | | | | 激励对象授予预留股票期权 | | | | 之 | | | | 独立财务顾问报告 | | | | 二零二五年八月 | | | | （二）关于本次授予事项与股东大会审议通过的激励计划是否存在差异的说明 | | ... 8 | | 一、释义 | | | | 本报告中，除非文义载明，下列简称具有如下含义： | | | | 万东医疗、公司 | | 指 北京万东医疗科技股份有限公司 | | 北京万东医疗科技股份有限公司 | | 2025 年股票期权激励计划（草 | | 本激励计划、本计划 | | 指 | | 案） | | | | | | 公司授予激励对象在未来一定期限内以预先确定的价格和条件购 | | 股票期权、期权 | | 指 | | 买公司一定数量股票的权利 | | | | | | 按照本激励计划规定，获得股票期权的公司（含子公司）董事、 | | 激励对象 | ...

证券代码：600055 证券简称：万东医疗 编号：临2025-037 北京万东医疗科技股份有限公司 关于向 2025 年股票期权激励计划 激励对象授予预留股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示： ? 预留授予日：2025年8月22日 ? 授予数量： 120万份 ? 行权价格：15.05元/份 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《北京万东医疗科技股份有限公司2025年股票期权激励计划（草案）》（ 以下简称"本次激励计划"或"激励计划（草案）"）等的相关规定，北 京万东医疗科技股份有限公司（以下简称"公司"）董事会认为本次激励 计划预留授予条件已经成就。根据公司2024年年度股东大会的授权，公司 于2025年8月22日召开第十届董事会第十次会议，审议通过了《关于向2025 年股票期权激励计划激励对象授予预留股票期权的议案》，确定以2025年 万份，行权价格为15.05元/份。现将有关情况公告如下： 一、本次激励计划已履行的审批程序和信息披露情况 《关于公司﹤20 ...

北京万东医疗科技股份有限公司 董事会薪酬与考核委员会 关于公司2025年股票期权激励计划 （3）最近12个月内因重大违法违规行为被中国证监会及其派出机构 行政处罚或者采取市场禁入措施； （4）具有《中华人民共和国公司法》规定的不得担任公司董事、 高级管理人员情形的； 预留授予激励对象名单（授予日）的核查意见 北京万东医疗科技股份有限公司（以下简称"公司"）董事会薪酬 与考核委员会依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股权激励管理办法》（以下简称"《管理办法》"）等有关法 律、法规及规范性文件和《北京万东医疗科技股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，对公司2025年股票期权激励计 划（以下简称"本次激励计划"）预留授予激励对象名单（授予日）进 行审核，发表核查意见如下： 一、本次激励计划预留授予的内容与公司2024年年度股东大会审议 通过的内容一致。 二、本次激励计划预留授予激励对象为当前在公司（含子公司）任 职的董事、高级管理人员、核心管理人员、核心技术/业务人员，不包 括公司独立董事、监事及单独或合计持有公司5%以上股份的股东或实际 控制人及其配偶、父母、子女 ...